Computational discovery of effective hepatitis C intervention strategies
Computational discovery of effective hepatitis C intervention strategies
批准号:
9383459
负责人:
Basmattee Boodram
金额:
$42.33万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-15 至 2022-07-31
关键词:
AddressAdherenceAntiviral AgentsBehavioralCaringCharacteristicsChicagoChronicClinical TrialsCommunitiesComplexComputer SimulationCost Effectiveness AnalysisCounselingDataData SetDevelopmentDevelopment PlansDiagnosisDirect CostsDisease ProgressionDrug usageEventExposure toFundingGeneral PopulationGeographic FactorGeographic LocationsGeographyGoalsGroupingHarm ReductionHealthHealth ServicesHepatitis CHepatitis C IncidenceHepatitis C PrevalenceHepatitis C TransmissionIllinoisImmune System DiseasesIncidenceIndividualInfectionInjecting drug userInjection of therapeutic agentInterventionKineticsLeadLife StyleLiver diseasesMeta-AnalysisMethodologyMethodsModelingNeedle-Exchange ProgramsNetwork-basedOpioid RotationOralPhasePolicy DevelopmentsPolicy MakerPopulationPrevalencePreventionPrisonsPublic HealthReportingResearchResearch PersonnelResourcesRiskRisk BehaviorsScienceSocial InteractionStrategic PlanningSystemTimeUnited States Dept. of Health and Human ServicesViralViral hepatitisWorkWorld HealthWorld Health Organizationbasechronic liver diseasedesigneffective interventionepidemiologic dataepidemiological modelimprovedlarge scale simulationmethicillin resistant Staphylococcus aureusmodels and simulationmortalitypathogenpreventprognosticprogramsscale upsocialtransmission processvaccine trial
中文摘要
7.项目摘要/摘要
丙型肝炎是世界范围内慢性肝病和死亡的主要原因。《世界卫生》
世界卫生组织最近认识到预防和控制丙型肝炎病毒感染的必要性,并建议
到2030年消除丙型肝炎是可行的,因为到2030年,新的慢性感染减少90%,丙型肝炎相关死亡率减少
65%。在美国,迫切需要以注射毒品者(PWID)为重点的消除战略,
感染和传播丙型肝炎病毒的高危人群。尽管危害长期存在
减少战略,如注射器交换计划(SEP)、阿片替代疗法(OSTS)和
行为咨询,丙型肝炎在美国的发病率在PWID中呈上升趋势。最近推出的所有口服药物
直接作用抗病毒药物(DAA),报告治愈率高(例如,90%),可预防肝病
进展和丙型肝炎病毒的传播,加上预防和减少危害的策略,使丙型肝炎病毒
消除贫穷是一个可以实现的目标.然而,鉴于存在相当大的障碍(例如,DAA的成本、与护理的联系不佳
和坚持、可能的再感染、PWID生活方式),这对于政策制定和战略规划是必不可少的
了解在PWID中最有效地促进丙型肝炎病毒消除的因素。了解
个人因素(如危险行为)、社会因素(如注入网络)、
结构(例如,获得注射器交换计划和阿片类药物替代疗法)和地理(例如,
非城市居民)水平对提高对消除丙型肝炎的了解和发展至关重要
战略。目前的模型无法解释这种动态和复杂的相互作用。因此,我们建议
开发一个全面的、基于数据驱动的基于代理的模型,用于在PWID(HepCEP)中消除丙型肝炎
芝加哥PWID人口作为一个模板和概念证明,使政策制定者能够确定
根据上述世卫组织的报告,到2030年消除丙型肝炎的最有效干预战略
拟议的削减估计数。这些努力的长期意义将是使HepCEP
(I)在芝加哥和伊利诺伊州监狱中建立丙型肝炎病毒传播模型的框架,(Ii)预测
丙型肝炎病毒在美国其他城市和非城市PWID人群(例如新墨西哥州阿尔伯克基)的传播,(Iii)执行
成本效益分析,以及(Iv)协助疫苗试验赞助商设计和评估临床试验。
英文摘要
7. PROJECT SUMMARY/ABSTRACT
Hepatitis C (HCV) is a leading cause of chronic liver disease and mortality worldwide. The World Health
Organization (WHO) has recently recognized the need to prevent and control HCV infection, and proposed that
HCV elimination is feasible by 2030 by reducing new chronic infections by 90% and HCV-related mortality by
65%. In the U.S., elimination strategies are urgently needed that focus on persons who inject drugs (PWID), the
group at most risk for acquiring and transmitting HCV infection. Despite the long-term availability of harm
reduction strategies such as syringe exchange programs (SEP), opioid substitution therapies (OSTs), and
behavioral counseling, HCV incidence in the U.S. is on the rise among PWID. The recent availability of all oral
direct-acting antivirals (DAAs) with high reported cure rates (e.g., >90%) that can prevent liver disease
progression and HCV transmission, combined with prevention and harm reduction strategies, make HCV
elimination an attainable goal. However, given considerable barriers (e.g., cost of DAAs, poor linkage to care
and adherence, possible reinfection, PWID lifestyle), it is essential for policy development and strategic planning
to understand the factors that would most effectively promote HCV elimination among PWID. Understanding the
dynamic and complex interplay of factors at the individual (e.g., risk behaviors), social (e.g., injection networks),
structural (e.g., access to syringe exchange programs and opioid substitution therapies), and geographic (e.g.,
non-urban residence) levels is essential to improve understanding and development of HCV elimination
strategies. Current models cannot account for such dynamic and complex interactions. As such we propose to
develop a comprehensive, data-driven agent-based model for Hepatitis C Elimination in PWID (HepCEP) using
the Chicago PWID population as a template and proof of concept that would enable policy makers to identify the
most effective intervention strategies for elimination of HCV by 2030 based on the aforementioned WHO's
proposed reduction estimates. The long term significance of these efforts would be to adapt the HepCEP
framework to (i) model HCV transmission in the general population of Chicago and in Illinois prisons, (ii) forecast
the spread of HCV in other U.S. urban and non-urban PWID populations (e.g., Albuquerque, NM), (iii) perform
cost-effectiveness analyses, and (iv) assist vaccine-trial sponsors in designing and evaluating clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions
-
批准号:10514625
-
项目类别:
-
资助金额:$70.81万
-
财政年份:2021
-
负责人:Basmattee Boodram
-
依托单位:
Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions
-
批准号:10367717
-
项目类别:
-
资助金额:$75.97万
-
财政年份:2021
-
负责人:Basmattee Boodram
-
依托单位:
Contextual risk factors for hepatitis C among young persons who inject drugs
-
批准号:10179349
-
项目类别:
-
资助金额:$52.6万
-
财政年份:2017
-
负责人:Basmattee Boodram
-
依托单位:
Contextual risk factors for hepatitis C among young persons who inject drugs
-
批准号:9926034
-
项目类别:
-
资助金额:$0.79万
-
财政年份:2017
-
负责人:Basmattee Boodram
-
依托单位:
Computational discovery of effective hepatitis C intervention strategies
-
批准号:10226066
-
项目类别:
-
资助金额:$39.86万
-
财政年份:2017
-
负责人:Basmattee Boodram
-
依托单位:
Case Management and Linkage to Care Among Persons Who Inject Drugs
-
批准号:8511081
-
项目类别:
-
资助金额:$14.79万
-
财政年份:2012
-
负责人:Basmattee Boodram
-
依托单位:
Case Management and Linkage to Care Among Persons Who Inject Drugs
-
批准号:8703331
-
项目类别:
-
资助金额:$15.18万
-
财政年份:2012
-
负责人:Basmattee Boodram
-
依托单位:
海外基金